UroGen Pharma (URGN) Operating Expenses (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Operating Expenses data on file, last reported at $67.1 million in Q1 2026.

• Quarterly Operating Expenses rose 22.33% year-over-year to $67.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $234.4 million (up 23.17% YoY) and the FY2025 annual result came in at $222.2 million, up 24.62% from the prior year.
• Operating Expenses rose to $67.1 million in Q1 2026, from $53.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $67.1 million in Q1 2026 to a low of $32.0 million in Q3 2023.
• A 5-year average of $43.7 million and a median of $40.3 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses slipped 4.12% — and 2024, when it soared 38.77%.
• Tracing URGN's Operating Expenses over 5 years: stood at $36.1 million in 2022, then slipped by 0.71% to $35.9 million in 2023, then soared by 38.77% to $49.8 million in 2024, then grew by 7.86% to $53.7 million in 2025, then gained by 25.01% to $67.1 million in 2026.
• The last three Operating Expenses figures came in at $67.1 million (Q1 2026), $53.7 million (Q4 2025), and $51.6 million (Q3 2025), per Business Quant data.